Nykode Therapeutics (NYKD) VB10.NEO presentation summary

Proprietary vaccine technology and programs

• APC-targeting technology enables precise immune modulation for oncology and autoimmunity applications.

• Key oncology programs include VB10.16 for HPV16+ cancers and VB10.NEO for individualized neoantigen therapy.

• Modular platform allows delivery via DNA, mRNA, viral vectors, or recombinant proteins.

Neoantigen selection and vaccine design

• Neoantigens are derived from tumor-specific genetic changes and are highly immunogenic due to lack of immune tolerance.

• NeoSELECT™ platform prioritizes neoantigens with proven immunogenicity, now protected by a new U.S. patent through 2039.

• Selection involves DNA/mRNA sequencing, HLA typing, and ranking based on multiple biological criteria.

Clinical trial results and safety

• VB10.NEO demonstrated robust immune responses in two basket trials with advanced solid tumors, including heavily pre-treated patients.

• 88–100% of patients showed vaccine-induced immune responses; 85% had de novo responses.

• Durable immune responses observed more than a year after final dose.

• VB10.NEO is safe and well-tolerated, with most adverse events being mild to moderate.